High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020-2021.
COVID-19
antibody persistence
household transmission
neutralizing antibodies
secondary attack rate
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
02
2022
accepted:
05
07
2022
entrez:
15
8
2022
pubmed:
16
8
2022
medline:
16
8
2022
Statut:
epublish
Résumé
Household transmission studies offer the opportunity to assess both secondary attack rate (SAR) and persistence of SARS-CoV-2 antibodies over time. In Spring 2020, we invited confirmed COVID-19 cases and their household members to four visits, where we collected nasopharyngeal and serum samples over 28 days after index case onset. We calculated SAR based on the presence of SARS-CoV-2 neutralizing antibodies (NAb) and assessed the persistence of NAb and IgG antibodies (Ab) against SARS-CoV-2 spike glycoprotein and nucleoprotein. SAR was 45% (39/87), including 35 symptomatic secondary cases. During the initial 28-day follow-up, 62% (80/129) of participants developed NAb. Of those that seroconverted, 90% (63/70), 85% (63/74), and 78% (45/58) still had NAb to early B-lineage SARS-CoV-2 3, 6, and 12 months after the onset of the index case. Anti-spike IgG Ab persisted in 100% (69/69), 97% (72/74), and 93% (55/59) of seroconverted participants after 3, 6, and 12 months, while anti-nucleoprotein IgG Ab levels waned faster, persisting in 99% (68/69), 78% (58/74), and 55% (39/71) of participants, respectively. Following detection of a COVID-19 case in a household, other members had a high risk of becoming infected. NAb to early B-lineage SARS-CoV-2 persisted for at least a year in most cases.
Sections du résumé
Background
UNASSIGNED
Household transmission studies offer the opportunity to assess both secondary attack rate (SAR) and persistence of SARS-CoV-2 antibodies over time.
Methods
UNASSIGNED
In Spring 2020, we invited confirmed COVID-19 cases and their household members to four visits, where we collected nasopharyngeal and serum samples over 28 days after index case onset. We calculated SAR based on the presence of SARS-CoV-2 neutralizing antibodies (NAb) and assessed the persistence of NAb and IgG antibodies (Ab) against SARS-CoV-2 spike glycoprotein and nucleoprotein.
Results
UNASSIGNED
SAR was 45% (39/87), including 35 symptomatic secondary cases. During the initial 28-day follow-up, 62% (80/129) of participants developed NAb. Of those that seroconverted, 90% (63/70), 85% (63/74), and 78% (45/58) still had NAb to early B-lineage SARS-CoV-2 3, 6, and 12 months after the onset of the index case. Anti-spike IgG Ab persisted in 100% (69/69), 97% (72/74), and 93% (55/59) of seroconverted participants after 3, 6, and 12 months, while anti-nucleoprotein IgG Ab levels waned faster, persisting in 99% (68/69), 78% (58/74), and 55% (39/71) of participants, respectively.
Conclusion
UNASSIGNED
Following detection of a COVID-19 case in a household, other members had a high risk of becoming infected. NAb to early B-lineage SARS-CoV-2 persisted for at least a year in most cases.
Identifiants
pubmed: 35966873
doi: 10.3389/fmed.2022.876532
pmc: PMC9366099
doi:
Types de publication
Journal Article
Langues
eng
Pagination
876532Informations de copyright
Copyright © 2022 Dub, Solastie, Hagberg, Liedes, Nohynek, Haveri, Virta, Vara, Lasander, Ekström, Österlund, Lind, Valtonen, Hemmilä, Ikonen, Lukkarinen, Palmu and Melin.
Déclaration de conflit d'intérêts
The Finnish Institute for Health and Welfare had received research funding for studies not related to COVID-19 from GlaxoSmithKline Vaccines (NE, CV, AP, and MM as investigators), Pfizer (AP), and Sanofi Pasteur (AP). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Microbiol. 2021 Nov 10;12:789374
pubmed: 34858383
Jpn J Infect Dis. 2021 Nov 22;74(6):579-583
pubmed: 33952770
Int J Infect Dis. 2021 Nov;112:8-12
pubmed: 34508860
J Virol. 2021 Jan 13;95(3):
pubmed: 33144321
Clin Infect Dis. 2021 Oct 5;73(7):1805-1813
pubmed: 33185244
Euro Surveill. 2020 Mar;25(11):
pubmed: 32209163
Viruses. 2021 Nov 19;13(11):
pubmed: 34835119
EClinicalMedicine. 2021 Nov;41:101174
pubmed: 34746725
Nat Commun. 2021 Mar 19;12(1):1724
pubmed: 33741972
Clin Infect Dis. 2022 Jan 7;74(1):52-58
pubmed: 33822007
EBioMedicine. 2020 Sep;59:102915
pubmed: 32747185
Lancet. 2014 Dec 6;384(9959):2024
pubmed: 25483164
MMWR Morb Mortal Wkly Rep. 2020 Nov 06;69(44):1631-1634
pubmed: 33151916
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Lancet Infect Dis. 2022 Feb;22(2):183-195
pubmed: 34756186
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
Sci Transl Med. 2022 Jul 21;:eabn4338
pubmed: 35862508
J Infect. 2021 Jul;83(1):e34-e36
pubmed: 33930468
PLoS Pathog. 2021 Mar 11;17(3):e1009413
pubmed: 33705496
J Glob Health. 2020 Dec;10(2):021103
pubmed: 33312513
Mater Sociomed. 2021 Mar;33(1):4-9
pubmed: 34012342
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Viruses. 2021 Oct 05;13(10):
pubmed: 34696428
Eur J Immunol. 2021 Dec;51(12):3202-3213
pubmed: 34580856
Clin Infect Dis. 2022 Apr 9;74(7):1220-1229
pubmed: 34218284
JAMA Netw Open. 2021 Aug 2;4(8):e2122240
pubmed: 34448865
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Transfusion. 2021 Sep;61(9):2677-2687
pubmed: 34121205
Cad Saude Publica. 2021 Mar 12;37(3):e00238720
pubmed: 33729282
Front Med (Lausanne). 2021 Jul 16;8:684864
pubmed: 34336891
Science. 2022 May 6;376(6593):eabn4947
pubmed: 35289632
Science. 2021 Jul 9;373(6551):
pubmed: 34035154
Clin Infect Dis. 2021 Aug 2;73(3):e699-e709
pubmed: 33400782
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Clin Infect Dis. 2021 Jul 30;73(Suppl 2):S138-S145
pubmed: 33045075
Microbiol Spectr. 2021 Dec 22;9(3):e0113121
pubmed: 34787485
JAMA Netw Open. 2020 Dec 1;3(12):e2031756
pubmed: 33315116
J Public Health (Oxf). 2021 Jun 7;43(2):243-245
pubmed: 33454742
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33058753
PLoS Pathog. 2021 Dec 2;17(12):e1010022
pubmed: 34855916
J Infect Dis. 2021 Aug 16;224(4):586-594
pubmed: 33978754
J Infect. 2020 Dec;81(6):979-997
pubmed: 32858069
Clin Infect Dis. 2021 Nov 2;73(9):e3066-e3073
pubmed: 33147319
J Korean Med Sci. 2021 May 31;36(21):e157
pubmed: 34060263
Lancet Reg Health Eur. 2021 Apr;3:100014
pubmed: 33871470
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Clin Infect Dis. 2022 May 30;74(10):1776-1785
pubmed: 34383889
Lancet Infect Dis. 2022 Jun;22(6):781-790
pubmed: 35366962
J Med Virol. 2021 Apr;93(4):2227-2233
pubmed: 33135795